Skip to main content

Table 3 Total-C (mg/dL) in the 19 patients who completed the study

From: LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia

 

Argicolina

Normolip

Argicolina−Normolip

At start of treatment

221.1 ± 16.5

221.6 ± 18.0

−0.5 (−9.8  +8.8)

At end of treatment

178.3 ± 16.3*

187.0 ± 17.1*

−8.7 (− 15.3  −2.1)

Δ Final–Initial

−42.7 (−53.6  −31.8)

−34.6 (−46.1  −23.1)

−8.2 (−19.9  +3.5)

% Δ (Final–Initial) / Initial

−19.0 (−23.5  −14.4)

−15.2 (−19.8  −10.5)

−3.8 (−8.2  +0.6)

  1. Data are expressed as mean ± SD, (95%CI), and analyzed by Student’s t test for paired data (end vs. start of treatment), * p < 0.0001